Pfizer Reports Strong Full-Year 2024 Results And Reaffirms 2025 Guidance
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/22/2026
- S&P 500, Nasdaq close lower, dragged by Alphabet and megacap tech; focus on Iran
- Oil settles down more 3% after US-Iran talks signal easing supply risks
- Micron surges 5.5% on blockbuster Anthropic AI deal ahead of earnings
- Alan Greenspan, influential former Federal Reserve chair, dies at 100
- Buy gold stocks as valuations are cheap amid macro tension: BofA
- CoreWeave trains DeepSeek-V3 in two minutes in MLPerf benchmark
- Needham Starts NeoVolta (NEOV) at Buy
- Spain's ex-transport minister sentenced to 24 years for corruption
- Li Auto Inc. (LI) Breaks Ground on Chips R&D and Production Base
- Exclusive-China robot-hand-building unicorn Linkerbot targets $6 billion valuation
Pfizer (PFE) Tops Q4 EPS by 15c, Beats on Revenue; Offers FY25 Guidance
February 4, 2025 6:46 AM ESTPfizer (NYSE: PFE) reported Q4 EPS of $0.63, $0.15 better than the analyst estimate of $0.48. Revenue for the quarter came in at $17.8 billion versus the consensus estimate of $17.28 billion.
GUIDANCE:
Pfizer sees FY2025 EPS of $2.80-$3.00, versus the consensus of $2.93. Pfizer... More
